(IMAX) Imax - Overview
Stock: Theater Systems, Film Remastering, Cameras, Streaming Software, Live Events
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 33.3% |
| Relative Tail Risk | -5.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.21 |
| Alpha | 37.95 |
| Character TTM | |
|---|---|
| Beta | 0.634 |
| Beta Downside | 0.978 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.93% |
| CAGR/Max DD | 0.87 |
Description: IMAX Imax January 15, 2026
IMAX Corporation (NYSE:IMAX) operates a global entertainment-technology platform spanning the United States, Greater China, the rest of Asia, Western Europe, Canada, Latin America and other international markets. Its business is split between a Content Solutions segment-offering proprietary film remastering, AI-driven video-quality tools, and the IMAX Enhanced home-entertainment ecosystem-and a Technology Products & Services segment that supplies theater-system sales, leasing, after-market parts, preventive maintenance, and camera rentals to museums, theme parks, and premium cinemas.
Key operational metrics (FY 2023) include total revenue of approximately $1.2 billion, with the Content Solutions segment contributing roughly 45 % of sales and growing at a 12 % compound annual rate over the past three years, driven by expanding streaming-content partnerships. The Technology Products & Services segment posted a 9 % year-over-year increase in theater-system installations, reflecting a rebound in premium-format attendance as global cinema traffic recovers from pandemic lows. A sector-wide driver is the rising consumer willingness to pay a premium for immersive experiences, which supports IMAX’s pricing power and its ability to command higher per-screen ticket premiums.
For a deeper quantitative assessment of IMAX’s valuation, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 39.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 8.07 > 1.0 |
| NWC/Revenue: 40.66% < 20% (prev 69.73%; Δ -29.08% < -1%) |
| CFO/TA 0.12 > 3% & CFO 109.2m > Net Income 39.5m |
| Net Debt (114.1m) to EBITDA (106.1m): 1.08 < 3 |
| Current Ratio: 1.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.6m) vs 12m ago 2.73% < -2% |
| Gross Margin: 58.84% > 18% (prev 0.54%; Δ 5830 % > 0.5%) |
| Asset Turnover: 43.43% > 50% (prev 40.77%; Δ 2.65% > 0%) |
| Interest Coverage Ratio: 10.06 > 6 (EBITDA TTM 106.1m / Interest Expense TTM 7.18m) |
Altman Z'' 1.19
| A: 0.17 (Total Current Assets 336.5m - Total Current Liabilities 183.1m) / Total Assets 889.6m |
| B: -0.27 (Retained Earnings -240.6m / Total Assets 889.6m) |
| C: 0.08 (EBIT TTM 72.2m / Avg Total Assets 868.6m) |
| D: 0.36 (Book Value of Equity 163.3m / Total Liabilities 452.9m) |
| Altman-Z'' Score: 1.19 = BB |
Beneish M -2.91
| DSRI: 0.40 (Receivables 136.9m/312.1m, Revenue 377.2m/345.6m) |
| GMI: 0.91 (GM 58.84% / 53.69%) |
| AQI: 2.18 (AQ_t 0.35 / AQ_t-1 0.16) |
| SGI: 1.09 (Revenue 377.2m / 345.6m) |
| TATA: -0.08 (NI 39.5m - CFO 109.2m) / TA 889.6m) |
| Beneish M-Score: -2.91 (Cap -4..+1) = A |
What is the price of IMAX shares?
Over the past week, the price has changed by +6.12%, over one month by +10.10%, over three months by +4.54% and over the past year by +46.43%.
Is IMAX a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the IMAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.1 | 18.3% |
| Analysts Target Price | 44.1 | 18.3% |
| ValueRay Target Price | 45 | 20.8% |
IMAX Fundamental Data Overview February 03, 2026
P/E Forward = 20.202
P/S = 4.9728
P/B = 5.2901
P/EG = 0.8895
Revenue TTM = 377.2m USD
EBIT TTM = 72.2m USD
EBITDA TTM = 106.1m USD
Long Term Debt = 230.7m USD (from longTermDebt, last quarter)
Short Term Debt = 230.7m USD (from shortTermDebt, last quarter)
Debt = 257.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 114.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.99b USD (1.88b + Debt 257.2m - CCE 143.1m)
Interest Coverage Ratio = 10.06 (Ebit TTM 72.2m / Interest Expense TTM 7.18m)
EV/FCF = 21.76x (Enterprise Value 1.99b / FCF TTM 91.6m)
FCF Yield = 4.60% (FCF TTM 91.6m / Enterprise Value 1.99b)
FCF Margin = 24.27% (FCF TTM 91.6m / Revenue TTM 377.2m)
Net Margin = 10.48% (Net Income TTM 39.5m / Revenue TTM 377.2m)
Gross Margin = 58.84% ((Revenue TTM 377.2m - Cost of Revenue TTM 155.3m) / Revenue TTM)
Gross Margin QoQ = 62.90% (prev 58.46%)
Tobins Q-Ratio = 2.24 (Enterprise Value 1.99b / Total Assets 889.6m)
Interest Expense / Debt = 0.71% (Interest Expense 1.83m / Debt 257.2m)
Taxrate = 18.71% (5.21m / 27.8m)
NOPAT = 58.7m (EBIT 72.2m * (1 - 18.71%))
Current Ratio = 1.84 (Total Current Assets 336.5m / Total Current Liabilities 183.1m)
Debt / Equity = 0.74 (Debt 257.2m / totalStockholderEquity, last quarter 349.5m)
Debt / EBITDA = 1.08 (Net Debt 114.1m / EBITDA 106.1m)
Debt / FCF = 1.25 (Net Debt 114.1m / FCF TTM 91.6m)
Total Stockholder Equity = 317.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.55% (Net Income 39.5m / Total Assets 889.6m)
RoE = 12.47% (Net Income TTM 39.5m / Total Stockholder Equity 317.2m)
RoCE = 13.17% (EBIT 72.2m / Capital Employed (Equity 317.2m + L.T.Debt 230.7m))
RoIC = 9.99% (NOPAT 58.7m / Invested Capital 587.5m)
WACC = 7.33% (E(1.88b)/V(2.14b) * Re(8.25%) + D(257.2m)/V(2.14b) * Rd(0.71%) * (1-Tc(0.19)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.53%
[DCF Debug] Terminal Value 73.41% ; FCFF base≈62.5m ; Y1≈41.0m ; Y5≈18.7m
Fair Price DCF = 5.61 (EV 416.1m - Net Debt 114.1m = Equity 302.0m / Shares 53.8m; r=7.33% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 46.03 | EPS CAGR: 79.67% | SUE: -4.0 | # QB: 0
Revenue Correlation: 37.53 | Revenue CAGR: -0.60% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.26 | Chg30d=-0.030 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=1.67 | Chg30d=+0.018 | Revisions Net=-2 | Growth EPS=+23.8% | Growth Revenue=+8.9%